These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 1734087)
1. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087 [TBL] [Abstract][Full Text] [Related]
2. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342 [TBL] [Abstract][Full Text] [Related]
3. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883 [TBL] [Abstract][Full Text] [Related]
4. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749 [TBL] [Abstract][Full Text] [Related]
6. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
7. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299 [TBL] [Abstract][Full Text] [Related]
8. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463 [TBL] [Abstract][Full Text] [Related]
9. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048 [TBL] [Abstract][Full Text] [Related]
10. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715 [TBL] [Abstract][Full Text] [Related]
11. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434 [TBL] [Abstract][Full Text] [Related]
12. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. Winick NJ; McKenna RW; Shuster JJ; Schneider NR; Borowitz MJ; Bowman WP; Jacaruso D; Kamen BA; Buchanan GR J Clin Oncol; 1993 Feb; 11(2):209-17. PubMed ID: 8426196 [TBL] [Abstract][Full Text] [Related]
13. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood. Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717 [TBL] [Abstract][Full Text] [Related]
14. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922 [TBL] [Abstract][Full Text] [Related]
15. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
17. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558 [TBL] [Abstract][Full Text] [Related]
18. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409 [TBL] [Abstract][Full Text] [Related]